Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
75 hedge funds and large institutions have $150M invested in Kezar Life Sciences in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 13 closing their positions.
240% more call options, than puts
Call options by funds: $34K | Put options by funds: $10K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0.21% more ownership
Funds ownership: 5.53% → 5.75% (+0.21%)
5% less capital invested
Capital invested by funds: $158M → $150M (-$7.87M)
10% less funds holding
Funds holding: 83 → 75 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.52M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.38M |
| 4 |
O
OrbiMed
New York
|
+$3.16M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.03M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.93M |
| 4 |
Two Sigma Investments
New York
|
-$517K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
-$324K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
76
Candriam SCA
Strassen, Luxembourg,
Luxembourg
| – | -$2.93M | -58,496 | Closed |
|
|
VEA
77
Virtus ETF Advisers
New York
| – | -$324K | -5,431 | Closed |
|
78
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$181K | -3,040 | Closed |
|
79
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$126K | -2,114 | Closed |
|
|
IHAM
80
Integral Health Asset Management
New York
| – | -$119K | -2,000 | Closed |
|
|
ECM
81
ExodusPoint Capital Management
New York
| – | -$105K | -1,767 | Closed |
|
|
RC
82
RBF Capital
San Francisco,
California
| – | -$72K | -1,215 | Closed |
|
83
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$67K | -1,077 | Closed |
|
84
Simplex Trading
Chicago,
Illinois
| – | -$2.33K | -41 | Closed |
|
|
MWP
85
Meridian Wealth Partners
Exton,
Pennsylvania
| – | -$1K | -23 | Closed |
|
86
Group One Trading
Chicago,
Illinois
| – | -$1.14K | -20 | Closed |
|
KZR Hedge Fund Activity: Q2 2021 in Review
75 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2021, worth a combined $150M — down 5% from $158M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KZR and 5 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 29 added.
The largest buyer was Morgan Stanley, adding an estimated $8.9M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $11.4M sold.
- 75 institutional investors held Kezar Life Sciences (KZR) as of Q2 2021, down from 83 in Q1 2021.
- Funds reported $150M of Kezar Life Sciences stock for Q2 2021, down 5% quarter-over-quarter.
- 5 funds opened new Kezar Life Sciences positions in Q2 2021 and 13 closed out, a net change of -8 holders.
- The largest Kezar Life Sciences buyer in Q2 2021 was Morgan Stanley, an estimated $8.9M added.
- The largest Kezar Life Sciences seller in Q2 2021 was Avidity Partners Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2021.